OncoMatch/Clinical Trials/NCT06810544
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Is NCT06810544 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including TNG456 and abemaciclib for non small cell lung cancer.
Treatment: TNG456 · abemaciclib — This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Glioblastoma
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP loss
Has a tumor with a confirmed MTAP loss
Required: IDH1 wild-type
confirmed glioblastoma (IDH-wildtype)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy
Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.
Cannot have received: PRMT5 inhibitor
Has received prior treatment with a PRMT5 inhibitor
Cannot have received: MAT2A inhibitor
Has received prior treatment with a MAT2A inhibitor
Cannot have received: CDK4/6 inhibitor
Exception: expansion cohort, combination therapy only
Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4/6 inhibitor
Lab requirements
Blood counts
adequate organ function/reserve per local labs
Kidney function
adequate organ function/reserve per local labs
Liver function
adequate organ function/reserve per local labs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Scottsdale · Scottsdale, Arizona
- University of California, Irvine · Irvine, California
- Sibley Memorial Hospital · Washington D.C., District of Columbia
- Mayo Clinic Jacksonville · Jacksonville, Florida
- Northwestern Memorial Hospital · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify